The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero ...

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until ...

While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, ...

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product ...

$20.79 198.22% HC Wainwright & Co.

Akero Therapeutics' week 96 Harmony trial data findings and reporting warrant caution due to biomarker data regression and inconsistent findings. In our view, Efruxifermin's phase 2 data reveal a ...

Sudbury Catholic District School Board has appointed David Madiba Akero, a Grade 10 student at St. Benedict Catholic ...

Los Angeles, California--(Newsfile Corp. - April 30, 2024) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...